Seres Therapeutics, Inc. (MCRB)
NASDAQ · Healthcare
Seres Therapeutics, Inc. Operating Income 2015–2025
Seres Therapeutics, Inc. annual/quarterly operating income history and growth rate from 2015 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Seres Therapeutics, Inc. operating income for the quarter ending March 31, 2026 was -20.9 M, a 23.24% decrease year-over-year.
- Seres Therapeutics, Inc. operating income for the twelve months ending March 31, 2026 was -99.8 M, a 70.96% increase year-over-year.
- Seres Therapeutics, Inc. annual operating income for 2025 was -94.0 M, a 22.54% decrease from 2024.
- Seres Therapeutics, Inc. annual operating income for 2024 was -121.3 M, a 37.82% decrease from 2023.
- Seres Therapeutics, Inc. annual operating income for 2023 was -195.1 M, a 8.44% increase from 2022.
- Seres Therapeutics, Inc. annual operating income for 2022 was -179.9 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Seres Therapeutics, Inc. Operating Income — FAQ
Seres Therapeutics, Inc. (MCRB) operating income over the last 11 years — annual and quarterly figures with year-over-year growth and charts.
What is Seres Therapeutics, Inc.'s operating income?
Seres Therapeutics, Inc. (MCRB) reported operating income of -$94M for fiscal 2025.
Where can I see MCRB's operating income history?
The chart and table above show Seres Therapeutics, Inc.'s operating income by year and by quarter, including the growth rate.